The rebound effect upon GLP-1R agonists withdrawal needs to be investigated further and new drug developments should aim to mitigate this big limitation and find ways in which GLP-1R agonists could be used as short-term therapies without causing weight regain and cardiometabolic risk reversal.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/vGk7839
via
Drug withdrawal rebound remains an unmet need in GLP-1R agonist space: GlobalData
December 21, 2023
0
Tags